158 related articles for article (PubMed ID: 35845479)
1. Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world.
Zhang P; Hou X; Cai B; Yu W; Chen J; Huang X; Li Y; Zeng M; Ren Z; Gabriel E; Qu B; Liu F
Ann Transl Med; 2022 Jun; 10(12):708. PubMed ID: 35845479
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world.
Wang HC; Huang X; Chen J; Li Y; Cong Y; Qu BL; Feng SQ; Liu F
World J Gastroenterol; 2023 Nov; 29(41):5641-5656. PubMed ID: 38077159
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study.
Lin W; Huang Y; Zhu L; Li W; Zhao L; Pan X; Lin J; Guo T
J Gastrointest Oncol; 2022 Dec; 13(6):2758-2768. PubMed ID: 36636044
[TBL] [Abstract][Full Text] [Related]
5. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
Zheng Y; Li C; Yu B; Zhao S; Li J; Chen X; Li H
JTCVS Open; 2022 Mar; 9():293-299. PubMed ID: 36003437
[TBL] [Abstract][Full Text] [Related]
6. Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2).
Gao L; Lu J; Zhang P; Hong ZN; Kang M
J Gastrointest Oncol; 2022 Apr; 13(2):478-487. PubMed ID: 35557591
[TBL] [Abstract][Full Text] [Related]
7. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
Lv H; Tian Y; Li J; Huang C; Sun B; Gai C; Li Z; Tian Z
Front Oncol; 2022; 12():864533. PubMed ID: 35574384
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
[TBL] [Abstract][Full Text] [Related]
13. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study.
Xia P; Li P; Wu S; Wang Y; Ye P; Zhang C; Hu J; Kidane B; Lampridis S; Velotta JB; Wakefield CJ; Zhu L; Wang L
Ann Transl Med; 2022 Sep; 10(18):991. PubMed ID: 36267734
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial inĀ Asia.
Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma.
Wu Z; Zheng Q; Chen H; Xiang J; Hu H; Li H; Pan Y; Peng Y; Yao X; Liu P; Sun Y; Li B; Zhang Y
J Thorac Dis; 2021 Jun; 13(6):3518-3528. PubMed ID: 34277047
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002).
Shang X; Zhang W; Zhao G; Liang F; Zhang C; Yue J; Duan X; Ma Z; Chen C; Pang Q; Zhang W; Liu L; Ren X; Meng B; Zhang P; Ma Y; Zhang L; Li H; Kang X; Li Y; Jiang H
Front Oncol; 2022; 12():831345. PubMed ID: 35433421
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma.
Huang B; Shi H; Gong X; Yu J; Xiao C; Zhou B; Liang Z; Li X
J Gastrointest Oncol; 2021 Oct; 12(5):2013-2021. PubMed ID: 34790369
[TBL] [Abstract][Full Text] [Related]
20. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).
Li C; Zhao S; Zheng Y; Han Y; Chen X; Cheng Z; Wu Y; Feng X; Qi W; Chen K; Xiang J; Li J; Lerut T; Li H
Eur J Cancer; 2021 Feb; 144():232-241. PubMed ID: 33373868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]